2018 Provenge (sipuleucel-T; Sanpower Group) Drug Analysis: A Cellular Immunotherapy Composed of Autologous Dendritic Cells Loaded with the Recombinant Antigen Prostatic Acid Phosphatase - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Provenge" drug pipelines has been added to ResearchAndMarkets.com's offering.

Drug Overview

Provenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed on approximately 95% of prostate tumor cells. The vaccine is administered alongside a granulocyte-macrophage colony-stimulating factor adjuvant. Upon injection, the PAP-loaded dendritic cells cause activation of T cells, which recognize the target antigen and destroy prostate tumor cells.

Key Topics Covered:

List of Figures

Figure 1: Provenge for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of Provenge for prostate cancer

Figure 3: Drug assessment summary of Provenge for prostate cancer

Figure 4: Provenge sales for prostate cancer in the US, 2017-26

List of Tables

Table 1: Provenge drug profile

Table 2: Provenge pivotal Phase III data in prostate cancer

Table 3: Provenge sales for prostate cancer in the US ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/dbmt8f/2018_provenge?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs , Cancer Vaccines

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs , Cancer Vaccines